{
    "nctId": "NCT04905329",
    "briefTitle": "A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations",
    "officialTitle": "Defendor Special: A Multicenter Prospective Observational Post-registration Study of Combined Chemotherapy With Empegfilrastim Support to Evaluate Safety and Efficacy in Patients With High and \"Gray Zone\" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies",
    "overallStatus": "UNKNOWN",
    "conditions": "Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 285,
    "primaryOutcomeMeasure": "Relative dose-intensity (RDI) of the myelosupressive therapy course",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed informed consent form;\n2. Histologically verified diagnosis;\n3. Age between 18 and 80 years; If the patient had previously received chemotherapy for these indications, then it should be completed at least 30 days before the first administration of the study drug;\n4. ECOG performance 0-2;\n5. Haematology:\n\n   * ANC \u2265 1,5 \u0445 10(9) /L;\n   * Platelets \u2265 100 \u0445 10(9) /L;\n   * Hemoglobin \u2265 90 g/L;\n6. Biochemistry:\n\n   * Creatinine \u2264 1,5 ULN;\n   * Total bilirubin \u2264 1,5 ULN;\n   * AST/ALT \u2264 2,5 ULN;\n   * Alkaline phosphatase \u2264 5 ULN;\n\n8. Life expectancy of at least 6 months from the date of the first drug administration in the study; 9. Ability of the patient to comply with the Protocol requirements.\n\nExclusion Criteria:\n\n1. Documented hypersensitivity to empegfilgrastim, filgrastim, pegfilgrastim, and / or their constituent excipients: pegylated drugs, protein recombinant drugs;\n2. Systemic use of antibiotics less than 72 hours before the first drug administration in the study;\n3. Concurrent or less than 30 days before the start of the study, radiation therapy (with the exception of point radiation therapy for bone metastases); study;\n4. Concurrent participation in clinical trials, participation in clinical trials within the previous 30 days, previous participation in this study;\n5. Surgical treatment less than 21 days (3 weeks) prior to study enrollment; taking any experimental medications less than 30 days before enrollment in this study;\n6. History of bone marrow or hematopoietic stem cell transplantation;\n7. Presence of acute or active chronic infections;\n8. Other diseases (with the exception of the main one) that could affect the assessment of the severity of the symptoms of the underlying disease: that may mask, enhance, change the symptoms of the underlying disease or cause clinical manifestations and changes in the data of laboratory and instrumental research methods;\n9. Inability to administer the drug by intravenous infusion or subcutaneous injection.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}